{"result": {"id": "9918ae92-19d9-4297-9599-1170ba50162d", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>EUR HEART J<|>ORGANIZATION<|>European Heart Journal is a peer-reviewed medical journal covering cardiovascular medicine>  \n##  \n(\"entity\"<|>BANGALORE S<|>PERSON<|>Bangalore S is a researcher involved in cholesterol guidelines and prognosis studies>)  \n##  \n(\"entity\"<|>FAYYAD R<|>PERSON<|>Fayyad R is a researcher involved in cholesterol guidelines and prognosis studies>)  \n##  \n(\"entity\"<|>KASTELEIN J J<|>PERSON<|>Kastelein J J is a researcher involved in cholesterol guidelines and prognosis studies>)  \n##  \n(\"entity\"<|>SCHWARTZ G G<|>PERSON<|>Schwartz G G is a researcher involved in cardiovascular outcomes studies>)  \n##  \n(\"entity\"<|>STEG P G<|>PERSON<|>Steg P G is a researcher involved in cardiovascular outcomes studies>)  \n##  \n(\"entity\"<|>SZAREK M<|>PERSON<|>Szarek M is a researcher involved in cardiovascular outcomes studies>)  \n##  \n(\"entity\"<|>ZHONG V W<|>PERSON<|>Zhong V W is a researcher involved in dietary cholesterol and cardiovascular disease studies>)  \n##  \n(\"entity\"<|>VAN HORN L<|>PERSON<|>Van Horn L is a researcher involved in dietary cholesterol and cardiovascular disease studies>)  \n##  \n(\"entity\"<|>CORNELIS M C<|>PERSON<|>Cornelis M C is a researcher involved in dietary cholesterol and cardiovascular disease studies>)  \n##  \n(\"entity\"<|>GINSBERG H N<|>PERSON<|>Ginsberg H N is a researcher involved in dietary cholesterol and lipid metabolism studies>)  \n##  \n(\"entity\"<|>KARMALLY W<|>PERSON<|>Karmally W is a researcher involved in dietary cholesterol and lipid metabolism studies>)  \n##  \n(\"entity\"<|>SIDDIQUI M<|>PERSON<|>Siddiqui M is a researcher involved in dietary cholesterol and lipid metabolism studies>)  \n##  \n(\"entity\"<|>MOZAFFARIAN D<|>PERSON<|>Mozaffarian D is a researcher involved in coronary heart disease and dietary fat studies>)  \n##  \n(\"entity\"<|>MICHA R<|>PERSON<|>Micha R is a researcher involved in coronary heart disease and dietary fat studies>)  \n##  \n(\"entity\"<|>WALLACE S<|>PERSON<|>Wallace S is a researcher involved in coronary heart disease and dietary fat studies>)  \n##  \n(\"entity\"<|>KIM B K<|>PERSON<|>Kim B K is a researcher involved in statin and ezetimibe therapy studies>)  \n##  \n(\"entity\"<|>HONG S J<|>PERSON<|>Hong S J is a researcher involved in statin and ezetimibe therapy studies>)  \n##  \n(\"entity\"<|>LEE Y J<|>PERSON<|>Lee Y J is a researcher involved in statin and ezetimibe therapy studies>)  \n##  \n(\"entity\"<|>CHRISTIAN J B<|>PERSON<|>Christian J B is a researcher involved in hypertriglyceridemia studies>)  \n##  \n(\"entity\"<|>ARONDE KAR B<|>PERSON<|>Aronde Kar B is a researcher involved in hypertriglyceridemia studies>)  \n##  \n(\"entity\"<|>BUYSMAN E K<|>PERSON<|>Buysman E K is a researcher involved in hypertriglyceridemia studies>)  \n##  \n(\"entity\"<|>BHATT D L<|>PERSON<|>Bhatt D L is a researcher involved in cardiovascular risk reduction studies>)  \n##  \n(\"entity\"<|>MILLER M<|>PERSON<|>Miller M is a researcher involved in cardiovascular risk reduction studies>)  \n##  \n(\"entity\"<|>YOKOYAMA M<|>PERSON<|>Yokoyama M is a researcher involved in coronary events and hypercholesterolemia studies>)  \n##  \n(\"entity\"<|>ORIGASA H<|>PERSON<|>Origasa H is a researcher involved in coronary events and hypercholesterolemia studies>)  \n##  \n(\"entity\"<|>MATSUZAKI M<|>PERSON<|>Matsuzaki M is a researcher involved in coronary events and hypercholesterolemia studies>)  \n##  \n(\"entity\"<|>KEECH A<|>PERSON<|>Keech A is a researcher involved in fenofibrate therapy and cardiovascular events studies>)  \n##  \n(\"entity\"<|>SIMES R J<|>PERSON<|>Simes R J is a researcher involved in fenofibrate therapy and cardiovascular events studies>)  \n##  \n(\"entity\"<|>BARTER P<|>PERSON<|>Barter P is a researcher involved in fenofibrate therapy and cardiovascular events studies>)  \n##  \n(\"entity\"<|>ACCORD STUDY GROUP<|>ORGANIZATION<|>The ACCORD Study Group is a research group studying combination lipid therapy in type 2 diabetes mellitus>)  \n##  \n(\"entity\"<|>CANNON C P<|>PERSON<|>Cannon C P is a researcher involved in cardiovascular studies>)  \n##  \n(\"entity\"<|>BLAZING M A<|>PERSON<|>Blazing M A is a researcher involved in cardiovascular studies>)  \n##  \n(\"relationship\"<|>BANGALORE S<|>FAYYAD R<|>Collaborated on cholesterol guidelines research<|>5>)  \n##  \n(\"relationship\"<|>BANGALORE S<|>KASTELEIN J J<|>Collaborated on cholesterol guidelines research<|>5>)  \n##  \n(\"relationship\"<|>FAYYAD R<|>KASTELEIN J J<|>Collaborated on cholesterol guidelines research<|>5>)  \n##  \n(\"relationship\"<|>SCHWARTZ G G<|>STEG P G<|>Collaborated on cardiovascular outcomes research<|>5>)  \n##  \n(\"relationship\"<|>SCHWARTZ G G<|>SZAREK M<|>Collaborated on cardiovascular outcomes research<|>5>)  \n##  \n(\"relationship\"<|>STEG P G<|>SZAREK M<|>Collaborated on cardiovascular outcomes research<|>5>)  \n##  \n(\"relationship\"<|>ZHONG V W<|>VAN HORN L<|>Collaborated on dietary cholesterol and cardiovascular disease research<|>5>)  \n##  \n(\"relationship\"<|>ZHONG V W<|>CORNELIS M C<|>Collaborated on dietary cholesterol and cardiovascular disease research<|>5>)  \n##  \n(\"relationship\"<|>VAN HORN L<|>CORNELIS M C<|>Collaborated on dietary cholesterol and cardiovascular disease research<|>5>)  \n##  \n(\"relationship\"<|>GINSBERG H N<|>KARMALLY W<|>Collaborated on dietary cholesterol and lipid metabolism research<|>5>)  \n##  \n(\"relationship\"<|>GINSBERG H N<|>SIDDIQUI M<|>Collaborated on dietary cholesterol and lipid metabolism research<|>5>)  \n##  \n(\"relationship\"<|>KARMALLY W<|>SIDDIQUI M<|>Collaborated on dietary cholesterol and lipid metabolism research<|>5>)  \n##  \n(\"relationship\"<|>MOZAFFARIAN D<|>MICHA R<|>Collaborated on coronary heart disease and dietary fat research<|>5>)  \n##  \n(\"relationship\"<|>MOZAFFARIAN D<|>WALLACE S<|>Collaborated on coronary heart disease and dietary fat research<|>5>)  \n##  \n(\"relationship\"<|>MICHA R<|>WALLACE S<|>Collaborated on coronary heart disease and dietary fat research<|>5>)  \n##  \n(\"relationship\"<|>KIM B K<|>HONG S J<|>Collaborated on statin and ezetimibe therapy research<|>5>)  \n##  \n(\"relationship\"<|>KIM B K<|>LEE Y J<|>Collaborated on statin and ezetimibe therapy research<|>5>)  \n##  \n(\"relationship\"<|>HONG S J<|>LEE Y J<|>Collaborated on statin and ezetimibe therapy research<|>5>)  \n##  \n(\"relationship\"<|>CHRISTIAN J B<|>ARONDE KAR B<|>Collaborated on hypertriglyceridemia research<|>5>)  \n##  \n(\"relationship\"<|>CHRISTIAN J B<|>BUYSMAN E K<|>Collaborated on hypertriglyceridemia research<|>5>)  \n##  \n(\"relationship\"<|>ARONDE KAR B<|>BUYSMAN E K<|>Collaborated on hypertriglyceridemia research<|>5>)  \n##  \n(\"relationship\"<|>BHATT D L<|>STEG P G<|>Collaborated on cardiovascular risk reduction research<|>5>)  \n##  \n(\"relationship\"<|>BHATT D L<|>MILLER M<|>Collaborated on cardiovascular risk reduction research<|>5>)  \n##  \n(\"relationship\"<|>STEG P G<|>MILLER M<|>Collaborated on cardiovascular risk reduction research<|>5>)  \n##  \n(\"relationship\"<|>YOKOYAMA M<|>ORIGASA H<|>Collaborated on coronary events and hypercholesterolemia research<|>5>)  \n##  \n(\"relationship\"<|>YOKOYAMA M<|>MATSUZAKI M<|>Collaborated on coronary events and hypercholesterolemia research<|>5>)  \n##  \n(\"relationship\"<|>ORIGASA H<|>MATSUZAKI M<|>Collaborated on coronary events and hypercholesterolemia research<|>5>)  \n##  \n(\"relationship\"<|>KEECH A<|>SIMES R J<|>Collaborated on fenofibrate therapy and cardiovascular events research<|>5>)  \n##  \n(\"relationship\"<|>KEECH A<|>BARTER P<|>Collaborated on fenofibrate therapy and cardiovascular events research<|>5>)  \n##  \n(\"relationship\"<|>SIMES R J<|>BARTER P<|>Collaborated on fenofibrate therapy and cardiovascular events research<|>5>)  \n##  \n(\"relationship\"<|>CANNON C P<|>BLAZING M A<|>Collaborated on cardiovascular research<|>5>)  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752165867, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 2450, "prompt_tokens": 2909, "total_tokens": 5359, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 1117}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: prescription of emerging lipid- lowering agents［J］. Eur Heart J，2016，37（17）：1373-1379. DOI：10.1093/eurheartj/ehw046.\n［9］BANGALORE  S，FAYYAD  R，KASTELEIN J J，et al. 2013 cholesterol guidelines revisited：percent LDL cholesterol reduction or attained  LDL  cholesterol level or both for prognosis  ？［J］ . Am J  Med，2016，129（4）：384-391 . DOI：10.1016/j.amjmed.2015.10.024.\n［10］SCHWARTZ G G，STEG P G，SZAREK M，et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome［J］. N Engl J Med，2018，379（22）：2097-2107. DOI：10.1056/ NEJMoa1801174.\n［11］ZHONG V W，VAN HORN L，CORNELIS M C ，et al. Associations of dietary cholesterol or egg consumption with incident cardiovascular disease and mortality［J］. JAMA，2019，321（11）： 1081-1095. DOI：10.1001/jama.2019.1572.\n［12］GINSBERG H N，KARMALLY W，SIDDIQUI M，et al. A dose- response study of the effects of dietary cholesterol on fasting and postprandial lipid and lipoprotein metabolism in healthy young\n\n\n\n·2436 · https://www.chinagp.net    E-mail: zgqkyx@chinagp.net.cn\n\nmen［J］. Arterioscler Thromb，1994，14（4）：576-586. DOI：10.1161/01.atv.14.4.576.\n［13］GINSBERG H N，KARMALLY W，SIDDIQUI M，et al. Increases in dietary cholesterol are associated with modest increases in both\n　LDL and HDL cholesterol in healthy young women［J］. Arterioscler Thromb Vasc Biol，1995，15（2）：169-178. DOI：10.1161/01. atv.15.2.169.\n［14］MOZAFFARIAN D，MICHA R，WALLACE S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat：a systematic review and meta-analysis of randomized controlled trials［J］ . PLoS Med，2010，7（3）：e1000252 . DOI： 10.1371/journal.pmed.1000252.\n［15］KIM B K，HONG S J，LEE Y J，et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease （RACING）：a randomised，open-label，non-inferiority trial［J］ . Lancet， 2022，400（10349）：380-390. DOI：10.1016/S0140-6736(22) 00916-3.\n［16］CHRISTIAN J B ，A RONDE KAR B ，BUYSMAN E K，  et al. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia［J］. J Clin Lipidol，2012，6（5）：450- 461. DOI：10.1016/j.jacl.2012.08.007.\n［17］BHATT D L，STEG P G，MILLER M，et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia［J］. N Engl J Med，2019，380（1）：11-22 . DOI：10.1056/ NEJMoa1812792.\n［18］YOKOYAMA M，ORIGASA H ，MATSUZAKI M，et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients （JELIS）：a randomised open- label，blinded endpoint analysis［J］. Lancet，2007，369（9567）： 1090-1098. DOI：10.1016/S0140-6736(07)60527-3.\n［19］KEECH A，SIMES R J，BARTER P，et al. Effects of long-term\nfenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus（the FIELD study）：randomised controlled trial［J］. Lancet，2005，366（9500）：1849-1861. DOI： 10.1016/S0140-6736(05)67667-2.\n［20］Accord Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus［J］. N Engl J Med，2010，362（17）：1563- 1574. DOI：10.1056/NEJMoa1001282.\n［21］CANNON  C  P ， BLAZING  M  A， GI\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_bfb81ca842457d5b094be52c959801be260e7e2a7afa92c17e448f348b55f476_v2"}